promisneurosciences.com - Bathi operasional EBITDA PMN

ProMIS Neurosciences (PMN) develops selective antibodies to combat brain edema associated with Alzheimer's disease. On GURU.Markets, the current EBITDA value reflects the dynamics of cash revenues, where 0.00 represents the current level of the metric. The company's growth relies on scientific alliances with neurological institutes, while investment interest is sustained by clinical trial successes and the potential for acquisition by pharma behemoths.

This metric is calculated as the difference between revenue and operating expenses before depreciation and amortization, measuring the business's actual ability to generate cash flow from its core operations. In the context of developing selective antibodies against Alzheimer's disease, the EBITDA_Co assessment allows investors to track the transition of ProMIS Neurosciences (PMN) from the investment stage to operational efficiency amid the scaling of innovative products.